
Sept 21 (Reuters) – The weight-loss drug market is booming, with biotech firms racing to capture a slice of the fast-growing sector dominated by Novo Nordisk and Eli Lilly. Analysts expect the
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Moody's downgrade puts Poland's inaction on debt surge in focus
* Spending surges ahead of next year's election * Moody's cites deficits, debt costs and…
US, China to meet again on AI safety in two months in Shenzhen, Bessent says
By David Lawder and Susan Heavey WASHINGTON, Sept 21 (Reuters) - Senior US and Chinese…
Oura targets $15.62 billion valuation in US IPO, setting stage for fall listings
By Manya Saini Sept 21 (Reuters) - Oura is targeting a fully diluted valuation of…